Increase in Growth for Global Cattle Industry Predicted at World Buiatrics Congress

Monheim, Germany, November 15 (ots/PRNewswire) - Bayer Animal
Health today outlined their vision for the future of cattle
production at the 26th World Buiatrics Congress in Santiago, Chile.
At the scientific symposium, Bayer confirmed their commitment to
transforming livestock production through bringing together world
cattle industry thought leaders alongside their expert scientists.
Presentations demonstrated how new approaches to livestock production
will help veterinarians and producers meet the demands of the rapidly
changing global market.

After the negative impact of the global financial crisis on the
meat industry in 2009, world experts presenting at the 3rd
International Bayer Cattle Symposium gave hope to producers
worldwide, covering subjects from production trends over the next 40
years to the transformative power of effective parasite and nutrient
management systems.

Dr Osler Desouzart, OD Consulting Brazil and a member of the
Advisory Board of the World Agricultural Forum, presented predictions
for global population growth and consumption over the next 40 years.
His research concluded that the dramatic increase in population
growth will drive continued growth in meat consumption. Dr Desouzart
predicts that "looking towards 2050, the meat consumption could
possibly double compared to 2008."

According to Dr Desouzart, adapting to the changing demands will
be imperative if the meat industry is to meet the new markets' needs,
as well as keeping pace with demand from traditional markets.
Furthermore, consumer attitudes in the developed world are changing.
"Today's consumers want to know what they eat, where does it come
from, how it was produced. They want assurances that it is safe for
their health as well as for the environment. Meat should come from
animals that are well cared for and are healthy. Animal health is no
longer a subject solely for veterinarians, it has become a core value
for the consumer", concluded Dr Desouzart.

This new consciousness in meat consumption was highlighted in a
presentation by Jerome Lyman, Corporate Vice President of Global
Quality Systems, McDonalds, US. "Our customers value the place of
beef in their diet; however, they are also expressing concerns about
issues such as zoonoses and the production methods used in the food
chain. McDonalds has long been at the forefront of efforts to
rationalise anti-infective use and we are seeing these attitudes
increasingly taking hold across the food industry. Cattle producers
need to be able to demonstrate that their products meet the highest
safety standards to match the consumers' drive to quality", said Mr
Lyman.

The central role of animal health in successful livestock
production was also reflected in the presentations of Drs Nicholas
Jonsson of the University of Glasgow, Scotland, and Marcelo Molento
of the Universidade Federal do Parana, Brazil, who discussed the need
for new approaches to parasite control. Veterinarians should
understand the needs of producers regarding ectoparasite control and
work with them focussing their specific needs. Dr Jonsson said, "All
too often cattle producers are not looking to veterinarians when it
comes to parasite control programmes, leading to suboptimal results.
This is a waste of time and money and undermines the welfare of their
livestock. Veterinarians should help their clients and work with them
on tailored programmes that give optimal, cost-effective control",
said Dr Jonsson. Dr Molento focused on the impact of technology
transfer to improve endoparasite control in cattle production
worldwide. "A clear example of the potential impact comes from
scientific literature where effective endoparasite control can be
seen with Eimeria spp. infection in cattle. These parasites cause
considerable economic damage to the cattle industry. Yet we know that
preventative treatment with toltrazuril in calves prevents disease
and leads to significant increases in weight gain in both dairy and
beef cattle", said Dr Molento.

Jim Gerardot, Head of Global Marketing - Food Animal Products,
Bayer Animal Health, said, "Bayer Animal Health continues to invest
in research. With this knowledge, we are able to offer our customers
the best possible solutions to meet their needs and provide education
to ensure they can maximise the benefits. The research presented at
WBC is another example of our global commitment to doing all we can
to support the continuing transformation of livestock production to
ensure a bright future for all our customers."

About Bayer HealthCare AG

The Bayer Group is a global enterprise with core competencies in
the fields of health care, nutrition and high-tech materials. Bayer
HealthCare AG, a subsidiary of Bayer AG with annual sales of about
EUR 15.9 billion (2009), is one of the world's leading, innovative
companies in the healthcare and medical products industry and is
based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and
manufacture products that will improve human and animal health
worldwide. Find more information at http://www.bayerhealthcare.com

With a turnover of EUR 977 million (2009) Bayer HealthCare's
Animal Health Division is one of the world's leading manufacturers of
veterinary drugs. The division manufactures and markets more than 100
different veterinary drugs and care products for livestock and
companion animals.

Forward-Looking Statements

This news release contains forward-looking statements based on
current assumptions and forecasts made by Bayer Group management.
Various known and unknown risks, uncertainties and other factors
could lead to material differences between the actual future results,
financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in
our annual and interim reports to the Frankfurt Stock Exchange and in
our reports filed with the U.S. Securities and Exchange Commission
(including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to confirm
them to future events or developments.

Contact:
Kathrin Statz
+49-2173-38-4019
kathrin.statz@bayerhealthcare.com

ots Originaltext: Bayer HealthCare
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact: Kathrin Statz,
+49-2173-38-4019,kathrin.statz@bayerhealthcare.com